Childhood Absence Epilepsy Clinical Trial
Official title:
Functional Neuroimaging in Childhood Absence Epilepsy
Verified date | January 2016 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Our study examines which different brain regions are involved in child absence seizures and how they are related to attention and cognition.
Status | Completed |
Enrollment | 180 |
Est. completion date | September 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 6 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Confirmed diagnosis of childhood absence epilepsy or juvenile absence epilepsy - No other serious health problems or neurological problems - 6 years or older Exclusion Criteria: - No history of myoclonic or tonic-clonic seizures |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Yale University School of Medicine, Neurology Department | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | National Institutes of Health (NIH) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT06153186 -
Flunarizine for Treatment Resistant Absence Epilepsy
|
Phase 2 | |
Enrolling by invitation |
NCT05109234 -
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
|
Phase 3 | |
Not yet recruiting |
NCT06315322 -
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
|
Phase 3 | |
Recruiting |
NCT04666610 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
|
Phase 3 | |
Completed |
NCT00088452 -
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
|
Phase 3 | |
Terminated |
NCT03355300 -
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
|
Phase 2 | |
Terminated |
NCT03336242 -
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
|
Phase 2 | |
Completed |
NCT00361010 -
A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy
|
N/A | |
Completed |
NCT00041951 -
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study
|
N/A | |
Recruiting |
NCT06310772 -
Assessing Comorbidities in Epilepsy Using Eye Movement Recordings
|